London, UK – October 5, 2022 – Paul Jones, CEO of Vortex Biosciences PLC, a portfolio company of NetScientific PLC (AIM:NSCI), recently shed light on the company’s advanced technology for capturing live circulating tumour cells (CTCs). This innovative approach is set to revolutionise personalised medicine in oncology.
Jones explained that Vortex’s core expertise lies in isolating intact, viable CTCs, providing an unprecedented opportunity to analyse these critical cancer indicators. Looking ahead, the company’s strategic focus is on building strong relationships with pharmaceutical and biotech companies developing cancer therapies. By offering bespoke lab-developed tests and in-vitro diagnostics, Vortex aims to provide crucial companion diagnostics that will guide treatment selection and monitor patient response.
This move towards a comprehensive CTC service offering underscores Vortex’s commitment to enabling more effective and targeted cancer care. By bridging the gap between cutting-edge research and clinical application, Vortex Biosciences is poised to play a pivotal role in the future of precision oncology, empowering clinicians and improving patient outcomes.
